SavedAdd your journal

Journals / Journal of Basic and Clinical Health Sciences / 2026 / Volume: 10 Issue: 2

Alkaline Phosphatase-To-Albumin Ratio (APAR) As A Prognostıc Biomarker in Metastatic Hormone-Sensitive Prostate Cancer

Faruk Recep Özalp(DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-2863-3243
Ahmet Melih Arslan(DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-6126-4611
Özge Yetginoğlu(DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-0684-8710
Hüseyin Salih Semiz(DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-7083-8517
Pages
—
Publication Date
2026-05-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall survival (OS) was assessed using Kaplan–Meier methods and multivariable Cox regression adjusting for standard prognostic factors, including tumor volume and Gleason score.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Metastatic hormone-sensitive prostate cancer (mHSPC) requires accessible biomarkers for better prognostication.
📊
Key Findings & Data:Methods: We retrospectively analyzed 128 mHSPC patients.
💡
Conclusion & Impact:Overall survival (OS) was assessed using Kaplan–Meier methods and multivariable Cox regression adjusting for standard prognostic factors, including tumor volume and Gleason score.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Alkaline phosphatase-to-albumin ratio (APAR) · Metastatic hormone-sensitive prostate cancer (mHSPC) · Prognostic biomarker

Abstract

Background: Metastatic hormone-sensitive prostate cancer (mHSPC) requires accessible biomarkers for better prognostication. This study investigated the prognostic value of the alkaline phosphatase-to-albumin ratio (APAR) in mHSPC survival risk stratification. Methods: We retrospectively analyzed 128 mHSPC patients. A cut-off of 2.92 for APAR was determined via ROC analysis. Overall survival (OS) was assessed using Kaplan–Meier methods and multivariable Cox regression adjusting for standard prognostic factors, including tumor volume and Gleason score. Results: Patients with APAR ≥2.92 had significantly shorter OS compared to those with APAR <2.92 (log-rank p<0.001). In multivariable analysis, APAR ≥2.92 remained an independent predictor of poor OS (HR 3.26, 95% CI 1.76–5.97; p<0.001), alongside ECOG status. Conclusions: APAR is an inexpensive, accessible marker that independently predicts survival in mHSPC. It holds promise for early risk stratification, though prospective validation is warranted.

Özet

Here is the revised abstract, shortened by approximately 20% while retaining critical statistical data (HR, p-values) and adhering to medical journal standards. English Abstract Background: Metastatic hormone-sensitive prostate cancer (mHSPC) requires accessible biomarkers for better prognostication. This study investigated the prognostic value of the alkaline phosphatase-to-albumin ratio (APAR) in mHSPC survival risk stratification. Methods: We retrospectively analyzed 128 mHSPC patients. A cut-off of 2.92 for APAR was determined via ROC analysis. Overall survival (OS) was assessed using Kaplan–Meier methods and multivariable Cox regression adjusting for standard prognostic factors, including tumor volume and Gleason score. Results: Patients with APAR ≥2.92 had significantly shorter OS compared to those with APAR <2.92 (log-rank p<0.001). In multivariable analysis, APAR ≥2.92 remained an independent predictor of poor OS (HR 3.26, 95% CI 1.76–5.97; p<0.001), alongside ECOG status. Conclusions: APAR is an inexpensive, accessible marker that independently predicts survival in mHSPC. It holds promise for early risk stratification, though prospective validation is warranted. Türkçe Özet (Turkish Abstract) Amaç: Metastatik hormona duyarlı prostat kanserinde (mHSPC) daha iyi prognoz tayini için erişilebilir biyobelirteçlere ihtiyaç duyulmaktadır. Bu çalışma, mHSPC sağkalım risk katmanlandırmasında alkalen fosfataz/albümin oranının (APAR) prognostik değerini araştırmayı amaçlamıştır. Yöntemler: Geriye dönük olarak 128 mHSPC hastası analiz edildi. ROC analizi ile APAR için 2.92 kesme değeri belirlendi. Genel sağkalım (OS), Kaplan-Meier yöntemi ve standart prognostik faktörlere (tümör volümü, Gleason skoru vb.) göre düzeltilmiş çok değişkenli Cox regresyonu ile değerlendirildi. Bulgular: APAR ≥2.92 olan hastalarda OS, APAR <2.92 olanlara kıyasla anlamlı derecede daha kısaydı (log-rank p<0.001). Çok değişkenli analizde, yüksek APAR (HR 3.26, %95 GA 1.76–5.97; p<0.001) ve ECOG performansı, kötü sağkalımın bağımsız öngörücüleri olarak saptandı. Sonuç: APAR, mHSPC'de sağkalımı bağımsız olarak öngören, düşük maliyetli ve ulaşılabilir bir belirteçtir. Erken risk katmanlandırması için umut vadetmekle birlikte ileriye dönük validasyon çalışmaları gereklidir.

🔖

Cite This Article

Özalp, F. R., Arslan, A. M., Yetginoğlu, Ö., Semiz, H. S. (2026). Alkaline Phosphatase-To-Albumin Ratio (APAR) As A Prognostıc Biomarker in Metastatic Hormone-Sensitive Prostate Cancer. Journal of Basic and Clinical Health Sciences, Volume: 10 Issue: 2. https://doi.org/10.30621/jbachs.1834209

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.
  2. Ng K, Smith S, Shamash J. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. Oncol Ther. 2020;8(2):209–30.
  3. Xia Q-D, Zhang S-H, Zeng N, Lu Y-C, Qin B-L, Wang S-G. Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future perspectives. Biomed Pharmacother. 2023;168:115806.
  4. Raval AD, Lunacsek O, Korn MJ, Littleton N, Constantinovici N, George DJ. Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023. JCO Oncol Pract. 2025;OP2400690.
  5. Das S, Ganguly SC, Bera S, Kundu M. Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics. Discov Oncol. 2025;16(1):954.
  6. Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9(8):565–73.
  7. Elewaily MI, Campione M, Hassan MA, Anpalakhan S, Atsumi N, Smalley B, et al. Prognostic factors and treatment choice for stage IV, low-volume metastasis hormone-sensitive prostate cancer: cross-sectional study of real-world data. Ther Adv Urol. 2024;16:17562872241297580.
  8. Alhanafy AM, Zanaty F, Ibrahem R, Omar S. Prognostic factors for hormone sensitive metastatic prostate cancer: impact of disease volume. Asian Pac J Cancer Prev. 2018;19(4):1113–8.
  9. Jiang T, Zeng Q, He J. Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors? Transl Cancer Res. 2023;12(10):2932–45.
  10. Andreescu J, Ocanto A, Couñago F. Prognostic significance of nutritional and inflammatory markers in colorectal cancer. World J Clin Oncol. 2025;16(6).
  11. Pu N, Gao S, Xu Y, Zhao G, Lv Y, Nuerxiati A, et al. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. J Cancer. 2017;8(16):3362–70.
  12. Wang Y, Bi X, Zhao H, Li Z, Zhao J, Zhou J, et al. Prognostic significance of the preoperative alkaline phosphatase to albumin ratio in patients with hepatocellular carcinoma after hepatic resection. Oncol Lett. 2023;25(4):147.
  13. Chikamatsu S, Shiota M, Yamada S, Blas L, Matsumoto T, Kashiwagi E, et al. Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer. Prostate Int. 2022;10(1):7–13.
  14. Wenzel M, Wagner N, Hoeh B, Siech C, Koll F, Cano Garcia C, et al. Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer. Prostate. 2024;84(14):1320–8.
  15. Guerra-Gómez M, Rodríguez-Pajuelo A, Brero-Sánchez L, Cuenca-Cuenca JI, Álvarez-Pérez RM, Freire-Macías JM, et al. Interobserver and intraobserver agreement in PET/CT with [18F]DCFPyL according to TNM molecular and PSMA-RADS 2.0 criteria. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024;43(5):500047.
  16. Kanesaka M, Sakamoto S, Yamada Y, Rii J, Maimaiti M, Sazuka T, et al. Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients. Prostate Int. 2021;9(4):208–14.
  17. Tang Q, Li X, Sun C-R. Predictive value of serum albumin levels on cancer survival: a prospective cohort study. Front Oncol. 2024;14:1323192.
  18. Kühn T, Sookthai D, Graf ME, Schübel R, Freisling H, Johnson T, et al. Albumin, bilirubin, uric acid and cancer risk: results from a prospective population-based study. Br J Cancer. 2017;117(10):1572–9.
  19. Ertürk SA, Şalk İ, Yücel B, Ulaş Babacan Ö, Hasbek Z. The Relationship between the SUVmax Value Obtained in Ga-68 PSMA PET/CT and Lactate Dehydrogenase and Alkaline Phosphatase in Prostate Cancer. Arch Esp Urol. 2022;75(6):552–8.
  20. Wang J, Wang B, Yuan S, Cheng G, Deng S, Wang Y, et al. Nonlinear association of alkaline phosphatase-to-albumin ratio with all-cause and cancer mortality: Evidence from NHANES 2005 to 2016. Medicine (Baltimore). 2024;103(46):e40430.
  21. Zhiyu Z, Qi Z, Jianglei Z, Jinxian PU, Jun O. Predictive value of preoperative albumin-to-alkaline phosphatase ratio on biochemical recurrence after radical prostatectomy. Journal of Dalian Medical University. 2021;43(5):413–8.
  22. Martínez-Corral R, Pérez-Fentes D, Bardella-Altarriba C, Vera-Ballesteros FJ, Abella-Serra A, Antón Fuente S, et al. PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point? Urol Oncol. 2026;44(2):124.e9-124.e15.
  23. Martínez-Corral R, De Pablos-Rodríguez P, Bardella-Altarriba C, Vera-Ballesteros FJ, Abella-Serra A, Rodríguez-Part V, et al. PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors. Urol Oncol. 2025;43(9):527.e9-527.e15.